Compare XNDU & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XNDU | SUPN |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | Canada | United States |
| Employees | 264 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | N/A | 2010 |
| Metric | XNDU | SUPN |
|---|---|---|
| Price | $10.77 | $44.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $44.00 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.1M | 677.5K |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | N/A | $22.70 |
| Revenue Next Year | N/A | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.97 | $35.51 |
| 52 Week High | $42.44 | $59.68 |
| Indicator | XNDU | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 39.38 |
| Support Level | $10.63 | $43.43 |
| Resistance Level | $11.27 | $46.79 |
| Average True Range (ATR) | 0.69 | 1.50 |
| MACD | 0.15 | -0.32 |
| Stochastic Oscillator | 69.51 | 5.69 |
Xanadu Quantum Technologies Ltd specializes in designing photonic devices and the platforms around them, including the experimentation and development of quantum computers available on the cloud with supporting software, along with quantum simulators and other related products and offerings. Its products include: Aurora, PennyLane, Catalyst, Lightning, Catalyst and PennyLane Codebook. The company operates in industries such as automotive, aerospace, energy, materials, and semiconductor sectors.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.